Literature DB >> 7690681

Urinary serotonin metabolite excretion during cisplatin chemotherapy.

O H Wilder-Smith1, A Borgeat, P Chappuis, M Fathi, M Forni.   

Abstract

BACKGROUND: Nausea and vomiting associated with cisplatin chemotherapy is a source of major morbidity that remains difficult to control. Acute phase (0-24 hours after induction of chemotherapy) nausea and vomiting parallels plasma serotonin release, which explains the effectiveness of 5HT3 antagonists; serotonin release in the delayed phase (24-48 hours after induction), during which consistent antiemetic control remains elusive, has not been investigated. The effect of propofol, a recent addition to the antiemetic armamentarium, on this serotonin release has not been studied.
METHODS: Ten women with nausea and vomiting refractory to ondansetron and dexamethasone prophylaxis in their first cisplatin chemotherapy cycle were studied. Serial urinary 5-hydroxyindoleacetic acid (5-HIAA) levels were determined during a 48-hour period in 30 subsequent cycles, conducted under ondansetron/dexamethasone prophylaxis together with a propofol infusion.
RESULTS: There was a significant urinary 5-HIAA peak 6 hours after induction of chemotherapy, with no peaks thereafter. Propofol did not inhibit serotonin release.
CONCLUSIONS: Cisplatin chemotherapy is associated with serotonin release in the acute phase. There is no serotonin release during the delayed phase. Thus the use of 5HT3 antagonists for delayed-phase nausea and vomiting would appear questionable.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690681     DOI: 10.1002/1097-0142(19931001)72:7<2239::aid-cncr2820720729>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret.

Authors:  J A Rudd; C C Jordan; R J Naylor
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients.

Authors:  Jin-Soo Kim; Ji Yeon Baek; Sook Ryun Park; In Sil Choi; Sang-Il Kim; Dong-Wan Kim; Seock-Ah Im; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang; Noe Kyeong Kim
Journal:  Cancer Res Treat       Date:  2004-12-31       Impact factor: 4.679

Review 3.  5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.

Authors:  R E Gregory; D S Ettinger
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

Review 4.  Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients.

Authors:  Yuichiro Hiura; Shuji Takiguchi; Kazuyoshi Yamamoto; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Hiroshi Miyata; Yoshiyuki Fujiwara; Masaki Mori; Yuichiro Doki
Journal:  Int J Clin Oncol       Date:  2011-07-20       Impact factor: 3.402

5.  Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting.

Authors:  Gerald M Higa; Miklos L Auber; Gerry Hobbs
Journal:  Support Care Cancer       Date:  2012-02-14       Impact factor: 3.603

Review 6.  Diversity of enteroendocrine cells investigated at cellular and subcellular levels: the need for a new classification scheme.

Authors:  Linda J Fothergill; John B Furness
Journal:  Histochem Cell Biol       Date:  2018-10-24       Impact factor: 4.304

7.  Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron.

Authors:  C P Schröder; W T van der Graaf; I P Kema; A Groenewegen; D T Sleijfer; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  The role of serotonin as a mediator of emesis induced by different stimuli.

Authors:  A du Bois; H Kriesinger-Schroeder; H G Meerpohl
Journal:  Support Care Cancer       Date:  1995-09       Impact factor: 3.603

9.  [Vomiting after gynecologic laparoscopy and under general anesthesia is associated with changes in excretion of serotonin metabolites].

Authors:  D Rüsch; C Strasser; I Celik; M Lengkong; H Wulf; J Scholz
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

Review 10.  Delayed emesis following anticancer chemotherapy.

Authors:  M G Kris; K M Pisters; L Hinkley
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.